Rhumbline Advisers Lowers Stock Holdings in LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Rhumbline Advisers reduced its position in LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) by 4.7% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 72,123 shares of the medical instruments supplier's stock after selling 3,538 shares during the quarter. Rhumbline Advisers owned about 0.32% of LeMaitre Vascular worth $6,051,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. Smartleaf Asset Management LLC grew its holdings in shares of LeMaitre Vascular by 234.4% during the fourth quarter. Smartleaf Asset Management LLC now owns 418 shares of the medical instruments supplier's stock valued at $39,000 after buying an additional 293 shares during the last quarter. CBIZ Investment Advisory Services LLC lifted its position in LeMaitre Vascular by 38.5% during the fourth quarter. CBIZ Investment Advisory Services LLC now owns 421 shares of the medical instruments supplier's stock valued at $39,000 after purchasing an additional 117 shares during the period. Huntington National Bank lifted its position in LeMaitre Vascular by 64.9% during the fourth quarter. Huntington National Bank now owns 1,156 shares of the medical instruments supplier's stock valued at $107,000 after purchasing an additional 455 shares during the period. Empowered Funds LLC acquired a new position in LeMaitre Vascular during the fourth quarter valued at $150,000. Finally, Canada Pension Plan Investment Board lifted its position in LeMaitre Vascular by 112.5% during the fourth quarter. Canada Pension Plan Investment Board now owns 1,700 shares of the medical instruments supplier's stock valued at $157,000 after purchasing an additional 900 shares during the period. 84.64% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, CEO George W. Lemaitre sold 18,733 shares of the firm's stock in a transaction on Friday, May 16th. The stock was sold at an average price of $84.77, for a total transaction of $1,587,996.41. Following the completion of the transaction, the chief executive officer now directly owns 1,873,651 shares in the company, valued at $158,829,395.27. This trade represents a 0.99% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Over the last three months, insiders sold 100,000 shares of company stock worth $8,556,857. Company insiders own 9.50% of the company's stock.

LeMaitre Vascular Price Performance

Shares of NASDAQ:LMAT traded down $0.24 during midday trading on Friday, hitting $81.13. The company had a trading volume of 229,261 shares, compared to its average volume of 169,218. LeMaitre Vascular, Inc. has a twelve month low of $71.42 and a twelve month high of $109.58. The stock has a market cap of $1.83 billion, a price-to-earnings ratio of 44.33, a price-to-earnings-growth ratio of 2.22 and a beta of 0.83. The business's 50-day simple moving average is $83.86 and its 200-day simple moving average is $90.29.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last posted its quarterly earnings results on Thursday, May 1st. The medical instruments supplier reported $0.48 EPS for the quarter, missing the consensus estimate of $0.50 by ($0.02). LeMaitre Vascular had a net margin of 19.40% and a return on equity of 13.15%. The company had revenue of $59.87 million during the quarter, compared to analyst estimates of $57.61 million. During the same period in the prior year, the business posted $0.44 EPS. LeMaitre Vascular's revenue for the quarter was up 12.0% compared to the same quarter last year. As a group, sell-side analysts forecast that LeMaitre Vascular, Inc. will post 1.94 EPS for the current year.

LeMaitre Vascular Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, May 29th. Investors of record on Thursday, May 15th were given a $0.20 dividend. The ex-dividend date was Thursday, May 15th. This represents a $0.80 annualized dividend and a yield of 0.99%. LeMaitre Vascular's payout ratio is 40.40%.

Analysts Set New Price Targets

A number of research analysts recently issued reports on LMAT shares. Lake Street Capital boosted their target price on shares of LeMaitre Vascular from $105.00 to $110.00 and gave the company a "buy" rating in a research report on Friday, February 28th. Oppenheimer downgraded shares of LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a research report on Friday, February 28th. Finally, Barrington Research downgraded shares of LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a research report on Friday, February 28th. Five research analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to data from MarketBeat.com, LeMaitre Vascular currently has an average rating of "Hold" and a consensus target price of $97.83.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.